Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream

V. Di Lernia,C. Ricci,G. Albertini
DOI: https://doi.org/10.1111/j.1468-3083.2004.01025.x
2004-09-01
Journal of the European Academy of Dermatology and Venereology
Abstract:Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5% imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1‐year follow‐up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.
What problem does this paper attempt to address?